Central Lab Market Outlook:
Central Lab Market size was valued at USD 3.62 billion in 2025 and is expected to reach USD 6.3 billion by 2035, expanding at around 5.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of central lab is evaluated at USD 3.81 billion.
The growth of the market is primarily attributed to the worldwide growing prevalence of numerous genetic abnormalities and the development of novel drugs and devices to treat such types of abnormalities. For instance, in 2021, around 85 novel active substances (NASs) were officially launched globally, which was more than twice the number launched five years ago.
As the occurrence of various diseases rises, so does the demand for new drug discovery and development. Pharmaceutical companies have prioritized efficient service and high-quality data without having to compromise. Therefore, these companies employ central labs for the detection, testing, development, and production of novel drugs and devices. Central labs are intended to facilitate clinical trials for novel drugs as well as genetic testing for a number of genetic diseases. Therefore, ongoing clinical trials for the production of new drugs are estimated to lead to the growth of the market. For instance, till 2022, there have been approximately 134,359 (32%) clinical trials registered in the US region alone, whereas around 221,438 (52%) clinical trials are registered in non-US regions.
